[go: up one dir, main page]

MA43374A - Méthodes de traitement de tumeurs malignes - Google Patents

Méthodes de traitement de tumeurs malignes

Info

Publication number
MA43374A
MA43374A MA043374A MA43374A MA43374A MA 43374 A MA43374 A MA 43374A MA 043374 A MA043374 A MA 043374A MA 43374 A MA43374 A MA 43374A MA 43374 A MA43374 A MA 43374A
Authority
MA
Morocco
Prior art keywords
treatment
methods
malignant tumors
malignant
tumors
Prior art date
Application number
MA043374A
Other languages
English (en)
Inventor
Sung Eun Choe
Bin Wu
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MA43374A publication Critical patent/MA43374A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
MA043374A 2015-12-04 2016-12-02 Méthodes de traitement de tumeurs malignes MA43374A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263580P 2015-12-04 2015-12-04
US201662300721P 2016-02-26 2016-02-26

Publications (1)

Publication Number Publication Date
MA43374A true MA43374A (fr) 2018-10-10

Family

ID=57610403

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043374A MA43374A (fr) 2015-12-04 2016-12-02 Méthodes de traitement de tumeurs malignes

Country Status (12)

Country Link
US (3) US10188656B2 (fr)
EP (2) EP3383433A1 (fr)
JP (4) JP6892448B2 (fr)
KR (2) KR20180088460A (fr)
CN (1) CN108883184A (fr)
AU (2) AU2016363011B2 (fr)
CA (2) CA3007218A1 (fr)
ES (1) ES2905915T3 (fr)
IL (4) IL298663A (fr)
MA (1) MA43374A (fr)
MX (2) MX380596B (fr)
WO (2) WO2017096150A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406389B1 (fr) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Procédés et compositions pour des troubles liés à la prolifération cellulaire
CA2793835C (fr) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Procedes et compositions pour des troubles relatifs
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2942072C (fr) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Compositions pharmaceutiques et utilisation de (s)-1-(2-chlorophenyle)-2-((3,3-di fluorocyclobutyle)amino)-2-oxoethyle)-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
WO2016053850A1 (fr) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs procédés d'utilisation
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
SG10201912869WA (en) 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
SG10201912886XA (en) 2015-10-15 2020-02-27 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
MA71411A (fr) 2015-10-15 2025-04-30 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
CN109715143A (zh) 2016-09-07 2019-05-03 细胞基因公司 片剂组合物
ES2968376T3 (es) 2017-05-05 2024-05-09 Memorial Sloan Kettering Cancer Center Métodos de tratamiento de neoplasia mieloproliferativa
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) * 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
EP3720442B1 (fr) 2018-05-16 2022-12-28 Forma Therapeutics, Inc. Inhibition de l'idh-1 mutante
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US12268690B2 (en) 2018-07-27 2025-04-08 Oregon Health & Science University Treatments for mutations in acute myeloid leukemia
WO2020092894A1 (fr) 2018-11-02 2020-05-07 Celgene Corporation Formes solides de 2-méthyl-1-[(4-[6-(trifluorométhyl)pyridin-2-yl]-6-{[2-(trifluorométhyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol
WO2020092906A1 (fr) 2018-11-02 2020-05-07 Celgene Corporation Co-cristaux de 2-méthyl-1-[(4-[6-(trifluorométhyl)pyridin-2-yl]-6-{[2-(trifluorométhyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino] propan-2-ol, compositions et procédés d'utilisation de ceux-ci
WO2020092915A1 (fr) 2018-11-02 2020-05-07 Celgene Corporation Dispersions solides pour le traitement du cancer
EP3886840A4 (fr) * 2018-11-30 2022-08-24 Aptose Biosciences Inc. Polythérapie avec des composés 2,3-dihydro-isoindole-1-one et procédés de traitement de patients présentant diverses mutations
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
CN115968292A (zh) * 2020-07-24 2023-04-14 隆萨本德公司 含乙酸的api过饱和溶液的喷雾干燥
WO2024229332A1 (fr) * 2023-05-03 2024-11-07 Memorial Sloan-Kettering Cancer Center Traitements anticancéreux et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (fr) 1997-06-06 2014-10-29 Depomed, Inc. Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
EP2406389B1 (fr) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Procédés et compositions pour des troubles liés à la prolifération cellulaire
CA2793835C (fr) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Procedes et compositions pour des troubles relatifs
SG11201403878QA (en) 2012-01-06 2014-08-28 Agios Pharmaceuticals Inc Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AU2013232379A1 (en) 2012-03-12 2014-09-25 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
NZ715738A (en) 2013-07-11 2021-06-25 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
CA2842635A1 (fr) 2014-01-20 2015-07-20 University Health Network Cellules precancereuses et leur identification dans la prevention et le traitement du cancer
WO2015127172A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs procédés d'utilisation
WO2015127173A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Composés thérapeutiquement actifs et leurs procédés d'utilisation
RS62178B1 (sr) 2014-03-14 2021-08-31 Les Laboratoires Servier Sas Farmaceutske kompozicije terapeutski aktivnih jedinjenja
CA2942072C (fr) * 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Compositions pharmaceutiques et utilisation de (s)-1-(2-chlorophenyle)-2-((3,3-di fluorocyclobutyle)amino)-2-oxoethyle)-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
WO2016053850A1 (fr) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs procédés d'utilisation
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
CA3007218A1 (fr) 2017-06-08
EP3383433A1 (fr) 2018-10-10
IL259783A (en) 2018-07-31
KR20180088460A (ko) 2018-08-03
MX380596B (es) 2025-03-12
IL298663A (en) 2023-01-01
US20220000878A1 (en) 2022-01-06
AU2016363011A1 (en) 2018-07-19
WO2017096309A8 (fr) 2018-06-14
US20170157132A1 (en) 2017-06-08
AU2016363011B2 (en) 2022-07-14
CA3007363A1 (fr) 2017-06-08
JP2021098740A (ja) 2021-07-01
JP6852073B2 (ja) 2021-03-31
CN108883184A (zh) 2018-11-23
MX2018006831A (es) 2019-05-06
WO2017096150A1 (fr) 2017-06-08
KR20180086255A (ko) 2018-07-30
IL299563A (en) 2023-02-01
AU2016362425A1 (en) 2018-06-21
JP2019502669A (ja) 2019-01-31
JP2019507721A (ja) 2019-03-22
MX2018006745A (es) 2018-09-05
JP2021121636A (ja) 2021-08-26
AU2016362425B2 (en) 2022-04-21
WO2017096309A1 (fr) 2017-06-08
US10188656B2 (en) 2019-01-29
EP3383400A1 (fr) 2018-10-10
IL259787A (en) 2018-07-31
ES2905915T3 (es) 2022-04-12
JP6892448B2 (ja) 2021-06-23
MX391229B (es) 2025-03-21
EP3383400B1 (fr) 2022-01-05
US20200268726A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
MA43374A (fr) Méthodes de traitement de tumeurs malignes
EP3288383A4 (fr) Méthodes de traitement du cancer
EP3423488A4 (fr) Méthodes de traitement du cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
EP3488001A4 (fr) Traitement du cancer
PL3288581T3 (pl) Sposób leczenia nowotworu
IL249065A0 (en) Combination therapies for the treatment of cancer
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
EP2943192A4 (fr) Méthodes de traitement du cancer du pancréas
IL258521B1 (en) Combination therapy for the treatment of cancer
EP3389634A4 (fr) Méthodes de traitement du cancer
IL263802A (en) Cancer treatment combinations
EP3405203A4 (fr) Méthodes de traitement du cancer
IL284875A (en) Lasofoxifene treatment of breast cancer
PT3458052T (pt) Tratamento combinado do cancro
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3606531A4 (fr) Méthodes de traitement du cancer
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
EP3440112A4 (fr) Méthodes de traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
MA71411A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
MA46361A (fr) Traitement du cancer de la prostate
EP3389652A4 (fr) Méthodes de traitement du cancer